- Our Doctors
- Dr Daniel Ajzensztejn
/content/dam/genesiscare/centres-and-staff/uk-centres-and-staff/Daniel Ajzensztejn.jpg
Dr Daniel Ajzensztejn
Dr Daniel Ajzensztejn
Daniel
Ajzensztejn
Consultant Clinical Oncologist
Languages spoken
English
Expert in
Lung and skin cancers
Overview
Centres
Milton Keynes
Milton Keynes
Sunrise Parkway, Linford Wood, Milton Keynes, Buckinghamshire, MK14 6LS, England, UK
52.05838, -0.76101
/uk/our-centres/milton-keynes
Buckinghamshire
Oxford
Oxford
Peters Way, Sandy Lane West, Oxford, Oxfordshire, OX4 6LB, England, UK
51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
Oxfordshire
Specialises in
Treatments
Dr Ajzensztejn is a Consultant Clinical Oncologist specialising in the treatment of lung and skin cancers. Dr Ajzensztejn has a substantive NHS post providing chemotherapy, radiotherapy and stereotactic ablative body radiotherapy (SABR) to patients for the treatment of skin, lung and palliative cancers. He works out of Milton Keynes and Oxford.
Dr Ajzensztejn is involved in a number of research trials including harnessing the immune system to reject cancers through genetic modifications of tumour cells. He is dedicated to providing the best possible care for his patients and is actively involved in research and learning new techniques and treatment modalities for his patients.
Career positions
Current position(s)
- University Hospitals Oxford
Qualifications
- 2016 FRCR. Royal College of Radiologists, Faculty of Clinical Oncology
- 2015 DPhil. Tumour Immunology. Green Templeton College, University of Oxford
- 2009 MSc Oncology. Institute of Cancer Research, University of London
- 2005 MRCP. Royal College of Physicians of London
- 1999 MBBS. University College London Medical School, University of London
- 1997 BSc Pharmacology (Hons). University College London, University of London
Expertise and interests
- Concurrent and sequential chemoradiotherapy
- Radical radiotherapy
- Adjuvant treatments
- Lung malignancies
- Respiratory medicine
- Harnessing the immune system to reject cancers through genetic modifications of tumour cells